Navigation Links
Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
Date:9/18/2012

NEW YORK, Sept. 18, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance

http://www.reportlinker.com/p0969026/Innovations-in-Drug-Delivery---Broad-based-Proprietary-Technology-Platforms-to-Address-Delivery-Efficiency-and-Improve-Patient-Compliance.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

 

Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance

 

Summary

 

GBI Research, the leading business intelligence provider, has released its latest research, "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance". The report provides an overview of the most exciting innovations in drug delivery technologies in major therapeutic areas – oncology, vaccines, diabetes, rheumatology and respiratory diseases. Each chapter highlights emerging companies with technologies that have the potential to transform drug delivery in that specific therapeutic area. The report also explores the current environment in healthcare and the pharmaceutical industry, and examines drivers and challenges for the use of innovative drug delivery technologies.

 

Drug delivery technologies provide commercial opportunities for pharmaceutical companies by improving the chances of success for a drug development project. They enable the formulation of a promising molecule that might have poor solubility or require selective delivery to a particular tissue, such as the brain. Similarly, drug delivery technologies may enable companies to differentiate products within crowded therapeutic areas, facilitate life cycle management for existing drugs, and reposition existing drugs – proprietary or generic – in new indications where the needs of the patient population are different or, again, where more targeted delivery is required. Products that are reformulated with novel drug delivery systems do not meet the traditional criteria for innovative products – in other words, products that include new active moieties. Nevertheless, GBI Research's analysis shows that the commercial success of existing products that rely on innovative drug delivery technologies is clear, and these products make significant positive changes for patients.

 

Scope

 

- Detailed analysis of the reasons for the industry to look closely at drug delivery technologies.

- Exploration of the environment in healthcare and the pharmaceutical industry that is driving companies to invest in drug delivery.

- Insight into collaborations between the largest pharmaceutical companies and smaller companies with innovative drug delivery technologies.

- Detailed insight into innovation in drug delivery in key therapeutic areas: oncology, vaccines, diabetes, rheumatology and respiratory diseases.

- Case studies of leading companies, their technologies and clinical data emerging from important drug development programs.

 

Reasons to buy

 

- Identify leading drug delivery companies.

- Learn about mergers, acquisitions and collaborations in drug delivery.

- Develop strategies and priorities for investing in drug delivery technologies.

- Understand the most important technologies and companies involved in developing new drug delivery technologies in key therapeutic areas.

- Explore the needs of patients in each therapeutic area and the ways in which drug delivery technologies can be used to meet these within drug development pipelines.

 

 

 

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Drug Delivery - An Overview 8

2.1 Introduction 8

2.2 The Drug Delivery Market 11

2.3 Market Trends Affecting Drug Delivery 12

2.3.1 Drivers within the Healthcare Environment 12

2.3.2 Pharmaceutical Industry 13

2.4 Leading Drug Delivery Companies 14

2.4.1 Pharmaceutical Company Drug Delivery Portfolios 16

2.4.2 Deal Making 16

3 Oncology 20

3.1 Introduction 20

3.2 PEGylation 23

3.3 Protein-Based Drug Delivery Systems 24

3.3.1 Albumin 24

3.3.2 Other Fusion Proteins 25

3.3.3 Hyaluronidase 25

3.4 Nanoparticles for Drug Delivery 26

3.4.1 Liposomes 26

3.4.2 Dendrimers 27

3.4.3 Polymer Delivery Systems 27

3.5 Tumor Targeting 28

3.5.1 Antibody-Drug Conjugates 29

3.6 Conclusions 30

4 Vaccines 31

4.1 DNA Vaccines 31

4.1.1 DNA Vaccines Delivered in Viral Vectors 32

4.1.2 Bacterial and Yeast-Based Antigen Delivery 34

4.2 'Naked' and Complexed DNA Vaccine Delivery 34

4.3 Vaccine Delivery to the Mucosal System and Skin 35

4.4 Intranasal Vaccine Delivery 35

4.5 Oral Vaccine Delivery 37

4.6 Transdermal Vaccine Delivery 39

4.6.1 Intercell 39

4.6.2 Microneedles for Intradermal Delivery 40

4.7 Conclusions 40

5 Diabetes 41

5.1 Introduction 41

5.2 Innovation in Insulin Delivery 41

5.2.1 Inhaled Insulin 41

5.2.2 Oral Insulin 43

5.2.3 Buccal Insulin 44

5.2.4 Transdermal Insulin 45

5.3 Next Generation Insulin Delivery Devices 45

5.3.1 Pens 45

5.3.2 Pumps 45

5.4 GLP-1 Analogues 46

5.5 Conclusions 48

6 Rheumatology 49

6.1 Introduction 49

6.2 Prefilled Syringes 50

6.3 Autoinjectors 50

6.3.1 New Materials in Autoinjector Design 52

6.4 Alternatives to Autoinjectors 53

6.4.1 Jet Injectors 53

6.4.2 Other Needle-Free Devices 54

6.4.3 Novel Injectors 55

6.5 Conclusions 55

7 Respiratory Diseases 57

7.1 Introduction 57

7.2 Drug Delivery Devices 57

7.2.1 Pressurized Metered Dose Inhalers 57

7.2.2 Dry Powder Inhalers 58

7.2.3 Aerosol Delivery Methods 58

7.2.4 Advances in Particle Engineering 60

7.2.5 Introduction of Electronics 61

7.3 Innovation in Drug Carriers for Pulmonary Drug Delivery 61

7.4 Alternative Routes of Delivery 61

7.5 Conclusions 62

8 Outlook 63

9 Appendix 65

9.1 Abbreviations 65

9.2 References 66

9.3 Methodology 68

9.3.1 Primary Research 68

9.3.2 Secondary Research 68

9.4 Contact Us 69

9.5 Disclaimer 69

 

List of Tables

 

1.1 List of Tables

Table 1: Innovation in Drug Delivery, Blockbuster Products Including Drug Delivery Systems, 2012 11

Table 2: Innovation in Drug Delivery, Examples of Leading Drug Delivery Companies, 2012 15

Table 3: Innovation in Drug Delivery, Examples of Licensing Deals for Drug Delivery, 2012 17

Table 4: Innovation in Drug Delivery, Examples of Licensing Deals for Drug Delivery, 2012 18

Table 5: Innovation in Drug Delivery, Examples of Oncology Drugs in Clinical Development with Drug Delivery Systems (by Technology Platform), 2012 21

Table 6: Innovation in Drug Delivery, Advances in PEGylation Technologies, 2012 23

Table 7: Innovation in Drug Delivery, Examples of Nanoparticulate Drug Delivery Systems, 2012 26

Table 8: Innovation in Drug Delivery, Approved Cancer Drugs with Liposomal Delivery Systems, 2012 26

Table 9: Innovation in Drug Delivery, Companies Developing Viral Vector Delivery Systems for Vaccines, 2012 33

Table 10: Innovation in Drug Delivery, Companies Developing Intranasal Vaccines and their Technologies, 2012 36

Table 11: Innovation in Drug Delivery, Companies Developing Oral Vaccines and their Technologies, 2012 38

Table 12: Innovation in Drug Delivery, Companies Developing Transdermal Vaccines and their Technologies, 2012 39

Table 13: Innovation in Drug Delivery, Inhaled Insulin Products and their Development Status, 2012 42

Table 14: Innovation in Drug Delivery, Oral Insulin Products and their Development Status, 2012 43

Table 15: Innovation in Drug Delivery, GLP-1 Analogs and their Development Status, 2012 47

Table 16: Innovation in Drug Delivery, Leading Drugs for Arthritis and their Delivery Systems, 2012 49

Table 17: Innovation in Drug Delivery, Leading Autoinjector Manufacturers and their Products, 2012 51

Table 18: Innovation in Drug Delivery, Examples of Liquid Jet Injectors for Needle Free Delivery, 2012 53

Table 19: Innovation in Drug Delivery, Companies Commercializing Aerosol Drug Delivery Technologies, 2012 59

Table 20: Innovation in Drug Delivery, Drug Delivery Requirements in Different Therapeutic Areas, 2012 63

 

List of Figures

 

1.2 List of Figures

Figure 1: Innovation in Drug Delivery, Commonly Used Options for Drug Delivery, 2012 8

Figure 2: Innovation in Drug Delivery, Uses of Drug Delivery Technology, 2012 9

Figure 3: Innovation in Drug Delivery, Commercial Opportunities for Drug Delivery Systems, 2012 10

Figure 4: Innovation in Drug Delivery, Reducing Drug Toxicity Through Drug Delivery, 2012 20

 

Companies Mentioned

 

N/A

 

 

 

To order this report:

Drug_Delivery_Technology Industry: Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend
2. Siemens Unveils New Solutions and Latest Innovations at AACC 2012
3. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
4. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
5. Innovations for Osteoarthritis, Sports Injuries and Orthopedic Practices
6. NFLPA and THERAPEARL, LLC Partner to Provide Athletes with Game Changing Innovations in Hot and Cold Pack Therapy
7. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
8. Freedom Innovations Wins the American Technology Award for Health & Medical Technologies
9. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
10. Elekta to Demonstrate Latest MOSAIQ OIS Innovations for Oncology Practices at 2012 ASCO Annual Meeting
11. Young Innovations, Inc. Board Of Directors Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... Grocery Company to the list of fine retailers selling biodegradable, hanging flushable wipes ... H.E.B., a large supermarket chain headquartered in San Antonio, Texas, operates more than ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – ... just 19 hours without sleep can compromise motor reaction time, which can increase the risk ... Insurance is sharing the following tips from the NSF to help you sleep better and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... MA (PRWEB) , ... April 28, 2017 , ... People ... for older people. “Wearing a hearing aid doesn’t have the stigma it had when ... & Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
Breaking Medicine News(10 mins):